publication . Article . Other literature type . 2016

Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)–Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection

Katherine V. Houser; Lisa M. Gretebeck; Tianlei Ying; Yanping Wang; Leatrice Vogel; Elaine W. Lamirande; Kevin W. Bock; Ian N. Moore; Dimiter S. Dimitrov; Kanta Subbarao;
Open Access
  • Published: 03 Mar 2016 Journal: Journal of Infectious Diseases, volume 213, issue 10, pages 1,557-1,561 (issn: 0022-1899, eissn: 1537-6613, Copyright policy)
  • Publisher: Oxford University Press (OUP)
Abstract
With >1600 documented human infections with Middle East respiratory syndrome coronavirus (MERS-CoV) and a case fatality rate of approximately 36%, medical countermeasures are needed to prevent and limit the disease. We examined the in vivo efficacy of the human monoclonal antibody m336, which has high neutralizing activity against MERS-CoV in vitro. m336 was administered to rabbits intravenously or intranasally before infection with MERS-CoV. Prophylaxis with m336 resulted in a reduction of pulmonary viral RNA titers by 40-9000-fold, compared with an irrelevant control antibody with little to no inflammation or viral antigen detected. This protection in rabbits ...
Persistent Identifiers
Subjects
Medical Subject Headings: viruses
free text keywords: Major Articles and Brief Reports, Immunology and Allergy, Infectious Diseases, Middle East respiratory syndrome coronavirus, medicine.disease_cause, medicine, Titer, Lung, medicine.anatomical_structure, Monoclonal antibody, medicine.drug_class, Middle East respiratory syndrome, medicine.disease, In vivo, business.industry, business, Case fatality rate, Antibody, biology.protein, biology, Virology, Immunology

1 WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). http://www.who.int/emergencies/mers-cov/en/Accessed 17 February 2016.

2 Assiri A, Al-Tawfiq JA, Al-Rabeeah AA et al Epidemiological, demographic, and clinical character istics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013; 13:752–61.23891402 [OpenAIRE] [PubMed]

3 Saad M, Omrani AS, Baig K et al Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis 2014; 29:301–6.25303830 [OpenAIRE] [PubMed]

4 Assiri A, McGeer A, Perl TM et al Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013; 369:407–16.23782161 [OpenAIRE] [PubMed]

5 Al-Abdallat MM, Payne DC, Alqasrawi S et al Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin Infect Dis 2014; 59:1225–33.24829216 [OpenAIRE] [PubMed]

6 van Doremalen N, Munster VJ Animal models of Middle East respiratory syndrome coronavirus infection. Antiviral Res 2015; 122:28–38.26192750 [OpenAIRE] [PubMed]

7 Haagmans BL, van den Brand JM, Provacia LB et al Asymptomatic Middle East respiratory syndrome coronavirus infection in rabbits. J Virol 2015; 89:6131–5.25810539 [OpenAIRE] [PubMed]

8 Pascal KE, Coleman CM, Mujica AO et al Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci U S A 2015; 112:8738–43.26124093 [OpenAIRE] [PubMed]

9 Ying T, Du L, Ju TW et al Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol 2014; 88:7796–805.24789777 [OpenAIRE] [PubMed]

10 Reed LJ, Muench H A simple method of estimation fifty per cent endpoints. American Journal of Hygiene 1938; 27:493–7.

11 Lu X, Whitaker B, Sakthivel SK et al Real-time reverse transcription-PCR assay panel for Middle East respiratory syndrome coronavirus. J Clin Microbiol 2014; 52:67–75.24153118 [OpenAIRE] [PubMed]

12 Marasco WA, Sui J The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 2007; 25:1421–34.18066039 [OpenAIRE] [PubMed]

13 Zhu Z, Chakraborti S, He Y et al Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A 2007; 104:12123–8.17620608 [OpenAIRE] [PubMed]

14 Leyva-Grado VH, Tan GS, Leon PE, Yondola M, Palese P Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies. Antimicrob Agents Chemother 2015; 59:4162–72.25941218 [OpenAIRE] [PubMed]

Abstract
With >1600 documented human infections with Middle East respiratory syndrome coronavirus (MERS-CoV) and a case fatality rate of approximately 36%, medical countermeasures are needed to prevent and limit the disease. We examined the in vivo efficacy of the human monoclonal antibody m336, which has high neutralizing activity against MERS-CoV in vitro. m336 was administered to rabbits intravenously or intranasally before infection with MERS-CoV. Prophylaxis with m336 resulted in a reduction of pulmonary viral RNA titers by 40-9000-fold, compared with an irrelevant control antibody with little to no inflammation or viral antigen detected. This protection in rabbits ...
Persistent Identifiers
Subjects
Medical Subject Headings: viruses
free text keywords: Major Articles and Brief Reports, Immunology and Allergy, Infectious Diseases, Middle East respiratory syndrome coronavirus, medicine.disease_cause, medicine, Titer, Lung, medicine.anatomical_structure, Monoclonal antibody, medicine.drug_class, Middle East respiratory syndrome, medicine.disease, In vivo, business.industry, business, Case fatality rate, Antibody, biology.protein, biology, Virology, Immunology

1 WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). http://www.who.int/emergencies/mers-cov/en/Accessed 17 February 2016.

2 Assiri A, Al-Tawfiq JA, Al-Rabeeah AA et al Epidemiological, demographic, and clinical character istics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013; 13:752–61.23891402 [OpenAIRE] [PubMed]

3 Saad M, Omrani AS, Baig K et al Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis 2014; 29:301–6.25303830 [OpenAIRE] [PubMed]

4 Assiri A, McGeer A, Perl TM et al Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013; 369:407–16.23782161 [OpenAIRE] [PubMed]

5 Al-Abdallat MM, Payne DC, Alqasrawi S et al Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin Infect Dis 2014; 59:1225–33.24829216 [OpenAIRE] [PubMed]

6 van Doremalen N, Munster VJ Animal models of Middle East respiratory syndrome coronavirus infection. Antiviral Res 2015; 122:28–38.26192750 [OpenAIRE] [PubMed]

7 Haagmans BL, van den Brand JM, Provacia LB et al Asymptomatic Middle East respiratory syndrome coronavirus infection in rabbits. J Virol 2015; 89:6131–5.25810539 [OpenAIRE] [PubMed]

8 Pascal KE, Coleman CM, Mujica AO et al Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci U S A 2015; 112:8738–43.26124093 [OpenAIRE] [PubMed]

9 Ying T, Du L, Ju TW et al Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol 2014; 88:7796–805.24789777 [OpenAIRE] [PubMed]

10 Reed LJ, Muench H A simple method of estimation fifty per cent endpoints. American Journal of Hygiene 1938; 27:493–7.

11 Lu X, Whitaker B, Sakthivel SK et al Real-time reverse transcription-PCR assay panel for Middle East respiratory syndrome coronavirus. J Clin Microbiol 2014; 52:67–75.24153118 [OpenAIRE] [PubMed]

12 Marasco WA, Sui J The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 2007; 25:1421–34.18066039 [OpenAIRE] [PubMed]

13 Zhu Z, Chakraborti S, He Y et al Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A 2007; 104:12123–8.17620608 [OpenAIRE] [PubMed]

14 Leyva-Grado VH, Tan GS, Leon PE, Yondola M, Palese P Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies. Antimicrob Agents Chemother 2015; 59:4162–72.25941218 [OpenAIRE] [PubMed]

Any information missing or wrong?Report an Issue